The Editor’s Roundtable: High-Density Lipoprotein Cholesterol

Abstract

r. Friedewald has no relevant financial relationship to isclose. Dr. Brewer has received fees for consulting from erck, White House Station, New Jersey; Merck/Schering lough, North Wales, Pennsylvania; Lipid Sciences, Pleasnton, California; Pfizer, Inc., New York, New York; Noartis, East Hanover, New Jersey; sanofi-aventis, Bridgewaer, New Jersey. Dr. Grundy has received research grants rom Merck, White House Station, New Jersey; Abbott, bbott Park, Illinois; KOS Pharmaceuticals, Weston, Florda; and has worked as a Consultant for Merck; Merck/ chering Plough, Kenilworth, New Jersey; KOS Pharmaeuticals; Pfizer, Inc., New York, NY; Eli Lilly, ndianapolis, Indiana; GlaxoSmithKline, Research Triangle ark, North Carolina; Abbott; Fournier, Montreal, Quebec, anada; Bristol-Myers Squibb, Plainsboro, New Jersey; ankyo, Parsippany, New Jersey; AstraZeneca, Wilmingon, Delaware; and sanofi-aventis, Bridgewater, New Jerey. Dr. Rader has received fees for speakers bureau from straZeneca, Wilmington, Delaware; Merck, White House tation, New Jersey; Merck/Schering Plough, North Wales, ennsylvania; Pfizer, Inc., New York, New York; has orked on the Advisory Committees for AstraZeneca; oehringer Ingelheim, Ridgefield, Connecticut; Bristol Myrs Squibb, Plainsboro, New Jersey; KOS Pharmaceuticals, eston, Florida; Merck; Merck/Schering Plough, North ales, Pennsylvania; Pfizer; Schering-Plough, Kenilworth, ew Jersey; and has worked as a Consultant for